Cargando…

A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly

PURPOSE: This systematic literature review investigated whether extended dosing intervals (EDIs) of pharmacological acromegaly treatments reduce patient burden and costs compared with standard dosing, while maintaining effectiveness. METHODS: MEDLINE/Embase/the Cochrane Library (2001–June 2021) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleseriu, M., Zhang, Z., Hanman, K., Haria, K., Houchard, A., Khawaja, S., Ribeiro-Oliveira, A., Gadelha, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708130/ https://www.ncbi.nlm.nih.gov/pubmed/36447058 http://dx.doi.org/10.1007/s11102-022-01285-1

Ejemplares similares

PMON66 A Systematic Literature Review to Evaluate Extended Dosing Intervals in the Pharmacological Management of Acromegaly
por: Fleseriu, Professor Maria, et al.
Publicado: (2022)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
por: Bernabéu, Ignacio, et al.
Publicado: (2020)

Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis
por: Fleseriu, Maria, et al.
Publicado: (2023)

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
por: Neggers, Sebastian JCMM, et al.
Publicado: (2015)

THU061 Treatment Patterns In Acromegaly: Analysis Of Real-World US Insurance Claims From The MarketScan(®) Database
por: Fleseriu, Maria, et al.
Publicado: (2023)

Use of Oral Concomitant Medications in Patients With Acromegaly
por: Petersenn, Stephan, et al.
Publicado: (2021)

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
por: Fleseriu, Maria
Publicado: (2010)

The role of primary pharmacological therapy in acromegaly
por: de los Monteros, Ana Laura Espinosa, et al.
Publicado: (2013)

A Pituitary Society update to acromegaly management guidelines
por: Fleseriu, Maria, et al.
Publicado: (2020)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Updates in Diagnosis and Treatment of Acromegaly
por: Zahr, Roula, et al.
Publicado: (2018)

Updates in rare and not-so-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly
por: Langlois, Fabienne, et al.
Publicado: (2020)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly
por: O’Toole, Dermot, et al.
Publicado: (2022)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

The genetic background of acromegaly
por: Gadelha, Mônica R., et al.
Publicado: (2017)

Novel therapies for acromegaly
por: Maia, Bernardo, et al.
Publicado: (2020)

Individualized acromegaly treatment: Is stereotactic radiation therapy changing the paradigm?
por: Liu, Winnie, et al.
Publicado: (2022)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
por: Marques, Nelma Veronica, et al.
Publicado: (2023)

Acromegaly and Colorectal Neoplasm: An Update
por: Kasuki, Leandro, et al.
Publicado: (2022)

Aggressive tumors and difficult choices in acromegaly
por: Carrasco, Carmen A., et al.
Publicado: (2013)

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
por: Colao, Annamaria, et al.
Publicado: (2020)

The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021)

Determinants of morbidities and mortality in acromegaly
por: Kasuki, Leandro, et al.
Publicado: (2019)

Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study
por: Giustina, Andrea, et al.
Publicado: (2019)

Extended-Interval Gentamicin Dosing for Pulmonic Tularemia
por: Dietrich, Tyson, et al.
Publicado: (2019)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

PMON57 Impact of Injection Modalities on Real-World Injection Experience in Patients with Acromegaly or Neuroendocrine Tumors (NETs) Treated With Somatostatin Analog (SSA) Therapy: Data from the PRESTO 2 Survey
por: Ribeiro-Oliveira, Antonio, et al.
Publicado: (2022)

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study
por: Caron, Philippe J., et al.
Publicado: (2015)

Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study
por: Petersenn, Stephan, et al.
Publicado: (2019)

MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population
por: Whittington, Melanie D, et al.
Publicado: (2020)

Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States
por: Fleseriu, Maria, et al.
Publicado: (2022)

Challenges in the diagnosis and management of acromegaly: a focus on comorbidities
por: Abreu, Alin, et al.
Publicado: (2016)

Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
por: Fleseriu, Maria, et al.
Publicado: (2016)

Multiple facets in the control of acromegaly
por: Vilar, Lucio, et al.
Publicado: (2013)

Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study
por: Caron, Philippe, et al.
Publicado: (2018)

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v6kpdcib03s6ddodnpjr73a2n8